Background A wide variety of oral diabetes medications are currently available for the
treatment of type 2 diabetes mellitus, but it is unclear how these agents compare with
respect to long-term cardiovascular risk. Our objective was to systematically examine the
peer-reviewed literature on the cardiovascular risk associated with oral agents (second-
generation sulfonylureas, biguanides, thiazolidinediones, and meglitinides) for treating
adults with type 2 diabetes. Methods We searched MEDLINE, EMBASE, and the Cochrane …